联合检测TRACP5b和CA-153诊断早期乳腺癌骨转移及评价双膦酸盐治疗疗效的临床研究  

The clinical research of serum TRACP5b and CA-153 to diagnose bone metastasis in early breast cancer and evaluate bisphosphonate therapy

作　　者：薛小萍[1] 

机构地区：[1]江苏省苏北人民医院临床医学检测中心,江苏扬州225001

出　　处：《实用临床医药杂志》2011年第21期52-54,共3页Journal of Clinical Medicine in Practice

摘　　要：目的探讨乳腺癌患者血清抗酒石酸酸性磷酸酶5b(TRACP5b)和糖类抗原-153(CA-153)在早期乳腺癌骨转移及评价双膦酸盐治疗疗效中的临床价值。方法采用酶联免疫吸附法(ELISA)及电化学发光免疫法检测23例健康女性、17例无骨转移及28例骨转移乳腺癌患者的血清TRACP5b及CA-153水平;对非骨转移和骨转移的乳腺癌患者进行随访;观察骨转移患者双膦酸盐治疗前后以上2种指标的改变。结果骨转移组TRACP5b浓度明显高于健康对照组(P<0.05)和无骨转移组(P<0.05);骨转移组CA-153浓度明显高于健康对照组(P<0.05),但与无骨转移组比较无统计学意义(P>0.05);血清TRACP5b的活性随骨转移速度而改变;TRACP5b与CA-153相比,敏感性有统计学意义(P<0.05),特异性无统计学意义(P>0.05);20名应用双膦酸盐治疗骨转移的患者,其治疗后血清TRACP5b和CA-153水平均较治疗前下降,但前者有统计学意义(P<0.05),后者无统计学意义(P>0.05)。结论联合使用TRACP5b和CA-153综合评价预测乳腺癌骨转移,可以提高早期诊断及疗效监测的可靠性。Objective To explore the diagnostic value of serum tartrate- resistant acid phosphatase 5b （TRACPSb） and cancer antigen 153（CA- 153） in patients with early bone metas- tases of breast cancer and the evaluation of the therapeutic efficacy of bisphosphonate. Methods The serum levels of TRACP5b and CA- 153 were determined by enzymelinked immunosorbent assay and eleetrochem iluminescence in 23 healthy female adults, 17 breast cancer patients without bone metastases and 28 breast cancer patients with bone metastases. Non - bone metastases and bone metastases of breast cancer patients were followed up. The change of above two kinds of indi- cators was observed in patients with bone metastases before and after treatment with bisphosphonate. Results The serum levels of TRACPSb of breast cancer patients with bone metastases were significantly higher than those of the other two groups （P〈0.05）. The serum levels of CA- 153 of breast cancer patients with bone metastases were significantly higher than those of healthy female adults （ P 〈 0.05）, but they were not significant compared with non - bone metastases （ P 〉0.05）. The activity of serum TRACPSb changed with the speed of bone metastases. Compared with CA- 153, the sensitivity of TRACP5b was statistically significant （ P 〈 0.05）, but specificity was not （P〉0.05）. The serum levels of TRACP5b and CA- 153 of 20 patients with bone metastases who were treated with bisphosphonate dropped compared with those before treatment, but the former were statistically significant （P 〈 0.05）, the latter were not （P 〉 0.05）. Conclusion To combine TRACPSb and CA- 153 in evaluating and forecasting breast cancer patients with bone metastases can improve reliability of early diagnosis and efficacy monitoring.

关 键 词：抗酒石酸酸性磷酸酶5B 糖类抗原-153 早期乳腺癌骨转移 

分 类 号：R737.9[医药卫生—肿瘤]